142 related articles for article (PubMed ID: 1290634)
1. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcemia.
Ostenstad B; Andersen OK
Acta Oncol; 1992; 31(8):861-4. PubMed ID: 1290634
[TBL] [Abstract][Full Text] [Related]
2. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
3. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
[TBL] [Abstract][Full Text] [Related]
4. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of available medical therapy for hypercalcemia of malignancy.
Mundy GR; Wilkinson R; Heath DA
Am J Med; 1983 Mar; 74(3):421-32. PubMed ID: 6219578
[TBL] [Abstract][Full Text] [Related]
7. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
8. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
9. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
10. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
Thiébaud D; Jacquet AF; Burckhardt P
Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
[TBL] [Abstract][Full Text] [Related]
11. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
13. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
14. The effect of low calcium diet, mithramycin, and dichlorodimethylene bisphosphonate on humoral hypercalcemia of malignancy in nude mice transplanted with the canine adenocarcinoma tumor line (CAC-8).
Rosol TJ; Capen CC
J Bone Miner Res; 1987 Oct; 2(5):395-405. PubMed ID: 2971305
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
16. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
[TBL] [Abstract][Full Text] [Related]
17. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Body JJ; Borkowski A; Cleeren A; Bijvoet OL
J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
19. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
Zojer N; Keck AV; Pecherstorfer M
Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
[TBL] [Abstract][Full Text] [Related]
20. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
